UPPSALA, Sweden, Sept. 3, 2004 (PRIMEZONE) -- Q-Med's nine-month interim report will be released on Wednesday, November 3 instead of, as previously announced, Thursday October 28.
The company further announces that Anne Rhenman has been appointed Director Investor Relations & Corporate Communications as from September 1st. Prior to joining Q-Med, Anne Rhenman held the same position at Axis Communications AB.
Queries should be addressed to: Erika Kjellberg Eriksson, CFO Ph: +46 (0) 70 974 90 20
Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approx. 500 employees, with approximately 320 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the Attract 40 list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/09/03/20040903BIT20370/wkr0001.pdf